Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
This research trial is looking at a new medicine called CABOMETYX for people with advanced thyroid cancer. This is for cancer that hasn't gotten better with standard radioactive iodine treatments. Scientists want to understand how CABOMETYX works in the body by looking at special markers in blood samples. They will compare these markers from before treatment, during treatment, and after treatment to see if they can predict how well the medicine works and if it's safe. The study aims to find better ways to treat this type of thyroid cancer and improve patients' quality of life.
At a glance
What is this study about?
This study, named 'Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer,' is exploring a medication called CABOMETYX. This medicine is for people who have advanced differentiated thyroid cancer that has not responded to radioactive iodine treatment, which is a common treatment for this type of cancer. The main goal is to understand how CABOMETYX works in a person's body at a very detailed level.
To do this, researchers will be looking closely at special markers in blood samples taken from participants. These samples will be collected at different times: before starting the medicine, after 24 weeks of treatment, at the end of the treatment, and potentially if you start a new treatment later on. By comparing these markers, the scientists hope to learn if certain changes in the blood can tell us more about whether the medicine is working, how long its effects last, and how it might impact the cancer over time.
Beyond finding out how well the medicine works, the study will also carefully track any side effects people experience and how the treatment affects their general well-being and quality of life. This helps paint a full picture of the medicine's impact. The information gathered from this study is crucial for doctors to understand if CABOMETYX could be a better treatment option for advanced thyroid cancer in the future.
Key takeaways
- This study is for advanced thyroid cancer not responding to standard iodine treatment.
- It tests a medicine called CABOMETYX to understand how it works.
- Blood samples help identify who might benefit most from the treatment.
- Your health and well-being will be closely monitored throughout.
- Participation involves taking tablets and giving regular blood samples.
Who may be eligible?
This study is looking for volunteers who are 18 years old or older. Both men and women can take part in this research.
To be considered, you must have advanced differentiated thyroid cancer and your cancer should not have responded well to radioactive iodine treatment. The doctors will check your medical history to make sure the study is suitable for you.
There will be other specific medical conditions and test results that the study team will need to check to make sure participating is safe and appropriate for your health. Your doctor can help you understand if you meet all the requirements.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have advanced differentiated thyroid cancer?
- Has your cancer not responded to radioactive iodine treatment?
- Are you able to take medicine in tablet form?
- Are you willing to provide blood samples at different times?
What does participation involve?
If you decide to take part in this study, you would be taking a medicine called CABOMETYX, which comes as tablets. There are different strengths (60 mg, 20 mg, or 40 mg) which your study doctor will decide is best for you.
Throughout the study, you would need to give blood samples at several key times: before you start taking the medicine, after 24 weeks of treatment, at the very end of your treatment, and potentially again if you start a different treatment more than three months after finishing the study medicine. You will also have regular check-ups to monitor your health, how the treatment is working, and to assess any side effects you might experience. The total duration of your participation would depend on how your treatment progresses and your individual response.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What kind of thyroid cancer is this study for?
This study is for advanced differentiated thyroid cancer that has not responded to radioactive iodine treatment.
What medicine is being tested?
The medicine being tested is called CABOMETYX, which comes in tablet form.
Why are blood samples needed?
Blood samples are taken to look for special markers that can help researchers understand how the medicine works and predict who might benefit most from it.
Will I know if the medicine is helping my cancer?
The study team will regularly monitor your health and how the treatment is affecting your cancer, and these results will be discussed with you.
Can I stop participating in the study?
Yes, you are free to leave the study at any time, for any reason, without it affecting your usual medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.